Q3 2024 Earnings Summary
- Maravai's investment in new capabilities like Flanders 1 and 2 has added to their cost base, but as revenues grow, margins are expected to expand significantly due to the fixed cost base already in place.
- The company's government contracts, including a 10-year agreement with BARDA, remain stable and provide long-term revenue opportunities, unaffected by political changes.
- The acquisition of Officinae Bio enhances Maravai's capabilities in AI-driven mRNA design, filling a gap in their portfolio and potentially accelerating growth in their Nucleic Acid Production segment.
- Lowered Revenue Guidance and Declining NAP Revenues: The company reduced its expected 2024 revenues to between $255 million and $265 million, primarily due to weaker market demand and delays in customer programs. The Nucleic Acid Production (NAP) segment is projected to see a decline in Q4 revenues to $43 million at the midpoint, down from $50 million in Q3, with the decline attributed more to weaker market conditions rather than just project delays.
- Limited Flexibility to Adjust Costs Amid Fixed Expenses: The company's cost structure includes significant fixed costs, such as labor and facility expenses, limiting its ability to reduce costs in response to revenue declines. Management does not anticipate changes in the business model to allow for more discretionary spending to offset revenue changes, emphasizing that margins depend on increasing revenues by filling capacity.
- Persistent Softness in the Biologics Market Affecting BST Segment: The Biologics Safety Testing (BST) segment is underperforming due to ongoing softness in the global biologics and bioprocessing markets. Revenues are expected to be down in the low single digits versus 2023, with the market weakness impacting the BST segment's financial performance.
-
Margin Expansion Outlook
Q: How should we think about margin expansion next year?
A: Management noted that margin expansion is primarily driven by revenue growth. With a cost base of approximately $235 million to $240 million, which is largely fixed and includes significant labor and facility costs, any increase in revenue will significantly improve margins due to their high variable margins and efficient cost structure. They emphasized that the dynamics supporting margin expansion have not changed. -
EBITDA Guidance and Flexibility
Q: How derisked is the 4Q EBITDA outlook?
A: Management believes the cost structure is appropriate and lean following last year's restructuring. They plan to continue investing in commercial efforts but do not anticipate significant changes in discretionary spending to offset revenue fluctuations. The focus remains on filling capacity and driving top-line growth, suggesting limited flexibility if revenues do not meet forecasts. -
4Q NAPs Business Swing Factors
Q: What are the swing factors for 4Q in the NAP business?
A: The company highlighted variability in the discovery business, estimating about $1 million variability on either side due to order patterns. They haven't seen larger orders ranging from $0.5 million to $5 million that typically drop in without much visibility. There's potential variability of a couple of million dollars in GMP builds as well. The remaining business shows normal volatility, but high-volume CleanCap orders are locked in. -
Soft Bioprocessing Market Impact
Q: What are you seeing in the soft bioprocessing backdrop?
A: They observed that early-phase program starts are down, affecting sales of Cygnus host cell protein detection kits, which are used more in preclinical to Phase II stages. Overall, the bioprocessing peer set is ranging from flat to mid- to high single-digit declines year-over-year, and Cygnus is performing in the middle of that range, aligning with industry norms. -
Officinae Bio Acquisition Details
Q: What drove the acquisition of Officinae Bio?
A: Management stated that they lacked a front-end design environment informed by bioinformatics. Acquiring Officinae Bio provides a Software-as-a-Service design platform that enhances their TriLink Discovery platform. The acquisition will enable seamless design experiences and rapid high-throughput mRNA construct optimization, expanding their market reach without significant customer overlap. -
Government Contracts Stability
Q: Do you expect any changes to government contracts like BARDA due to the recent election?
A: They do not anticipate any changes. BARDA recently celebrated the opening of Flanders 1 facility, emphasizing the 10-year pandemic preparedness arrangement, which is expected to remain unaffected by political changes. -
gRNA Trials and NAP Impact
Q: Are gRNA trial starts needle-moving for NAP next year?
A: Management believes the activity in guide RNA trials will positively impact NAP. While they haven't disclosed specific participation rates, they see the percentage participation of CleanCap in gRNA programs as likely the same as in mRNA programs, noting increased activity and growing use of mRNA in this area.
Research analysts covering MARAVAI LIFESCIENCES HOLDINGS.